Five Prime Therapeutics Announces Management Transition
September 19 2019 - 3:05PM
Business Wire
Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage
biotechnology company focused on discovering and developing immune
modulators and precision therapies for solid tumor cancers,
announced today that its Board of Directors has appointed William
“Bill” Ringo as Interim Chief Executive Officer, effective
immediately. Mr. Ringo will succeed Chief Executive Officer and
Board Member Aron Knickerbocker, who has resigned from the company
to pursue new challenges and opportunities. Mr. Ringo will continue
to serve as Chairman of Five Prime’s Board of Directors.
“I look forward to working with the talented executive team at
Five Prime as interim CEO to ensure that all clinical programs
remain on track as we enter a period where upcoming data events
will provide insights to enable prioritization of clinical
investments and pipeline programs,” said Mr. Ringo. “The Board is
initiating a search process to recruit a permanent Chief Executive
Officer.”
Mr. Ringo has served as the Chairman of the Five Prime Board of
Directors since January 2019 and as a Board Member since October
2014. He is an industry leader who has served in numerous executive
and board roles across the pharmaceutical, biotech and venture
capital sectors. Mr. Ringo served as President and Chief Executive
Officer of Abgenix and as Senior Vice President of Business
Development, Strategy and Innovation at Pfizer. He also served for
28 years at Eli Lilly and Company in numerous executive roles,
including Product Group President for Oncology and Critical Care,
President of Internal Medicine Products, President of the
Infectious Diseases Business Unit and Vice President of Sales and
Marketing for U.S. Pharmaceuticals.
“On behalf of the Board, I thank Aron for his dedication and
numerous contributions during ten years of service as Five Prime
evolved from a research-oriented private company to a public one
with multiple programs advancing in clinical development,” Mr.
Ringo continued. “As Chief Executive Officer, Aron provided
leadership for the expansion of our clinical portfolio and we wish
him well in his future endeavors.”
About Five Prime Therapeutics
Five Prime Therapeutics, Inc. discovers and develops innovative
protein therapeutics to improve the lives of patients with serious
diseases. Five Prime’s product candidates have innovative
mechanisms of action and address patient populations in need of
better therapies. Five Prime has five programs in various stages of
clinical development with two of these programs partnered with
Bristol-Myers Squibb. The company focuses on researching and
developing immuno-oncology and targeted cancer therapies paired
with companion diagnostics to identify patients who are most likely
to benefit from treatment with Five Prime’s product candidates.
Five Prime has entered into strategic collaborations with leading
global pharmaceutical companies and has promising product
candidates in clinical and preclinical development. For more
information, please visit www.fiveprime.com or follow us on
LinkedIn, Twitter and Facebook.
Cautionary Note on Forward-looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Words such as "may," "will," "expect," "plan," "anticipate,"
"estimate," "intend" and similar expressions (as well as other
words or expressions referencing future events, conditions or
circumstances) are intended to identify forward-looking statements.
These forward-looking statements are based on Five Prime's
expectations and assumptions as of the date of this press release.
Each of these forward-looking statements involves risks and
uncertainties. Actual results may differ materially from these
forward-looking statements. Factors that may cause actual results
to differ from those expressed or implied in the forward-looking
statements in this press release are discussed in Five Prime’s
filings with the U.S. Securities and Exchange Commission, including
the “Risk Factors” contained therein. Except as required by law,
Five Prime assumes no obligation to update any forward-looking
statements contained herein to reflect any change in expectations,
even as new information becomes available.
Source: Five Prime Therapeutics, Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190919005840/en/
Martin Forrest VP, Investor Relations & Corporate
Communications Five Prime Therapeutics, Inc. 415-365-5625
martin.forrest@fiveprime.com
Five Prime Therapeutics (NASDAQ:FPRX)
Historical Stock Chart
From Apr 2024 to May 2024
Five Prime Therapeutics (NASDAQ:FPRX)
Historical Stock Chart
From May 2023 to May 2024